Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535713 · ClinicalTrials.gov registry record · Phase 2
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
A Phase 2 study of Sarcoma, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 1
- Study location
NCT04535713 is a Phase 2 study of Sarcoma that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 260 participants, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04535713, a Phase 2 study of Sarcoma, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase 2 study for advanced sarcoma using metronomic doses of gemcitabine, doxorubicin and docetaxel, and nivolumab immunotherapy given intravenously.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Nivolumab
- DRUG Gemcitabine
Study Locations (1)
California
- Sant P Chawla - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535713
The ClinicalTrials.gov registry entry for NCT04535713 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (72% lower). The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT04535713 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04535713 about?
NCT04535713 is a clinical study titled "GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma". This is an open label phase 2 study for advanced sarcoma using metronomic doses of gemcitabine, doxorubicin and docetaxel, and nivolumab immunotherapy given intravenously.
What is the current status of trial NCT04535713?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2020-09-30. Estimated completion is 2025-12-31.
What conditions does trial NCT04535713 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT04535713?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin (DRUG), Nivolumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT04535713?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04535713 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.